

Specialty consulting in bioactive natural products derived from microbial sources

Curriculum vitae

Celso Almeida,

Orcid ID: 0000-0002-5935-612X

SPECIALTIES (for consulting and custom services)

- Bioactive natural products derived from microbial sources
- Endosymbiotic bacteria in fungal hosts

EDUCATION

- PhD "*Magna cum laude*", Institute for Pharmaceutical Biology, University of Bonn, Germany, mentor prof. Dr. Gabriele M. König (2011)
- MSc in Biodiversity and Natural Products, Division of Pharmacognosy, University of Leiden, The Netherlands, mentor prof. Dr. Rob Verpoorte (2005)
- Graduation in Biology from the University of Aveiro, Portugal (2003)

EXPERIENCE

- 15+ years' research in bioactive natural products derived from microbial sources, which include the cultivation, bioassay-guided isolation and structure elucidation of **45+ new fungal and bacterial-derived secondary metabolites**
- 8+ years pos doc experience in 4 labs, including 3+ years at Fundación Medina (Spain, ex-Merck's division of microbial natural products research)
- 10+ years' experience in the field of endobacterial symbionts in fungal hosts (see <https://aem.asm.org/content/84/15/e00660-18>)
- Founder of the Biotech Startup ENDOBIOS (www.endobios.com, 2018)



CUSTOM SERVICES in bioactive natural products derived from fungi and bacteria (provided by the ENDOBIOS® network) – chemistry, drug discovery, bioassays, etc.

See details in <https://endobios.com/consulting-services/>

EXAMPLE OF CONSULTING EXPERTISE

- To explain in detail the reality of microbial natural products research (**importantly, "be very careful with what you read in publications"**), in order to understand the most promising approaches, avoiding misdirected research;
- To custom-design and implement screening platform for microbial extracts at low cost, including High Throughput Screening cultivations;
- Platforms can be implemented in an academic or industrial environment;
- To propose a wide range of approaches and techniques in every step of the drug discovery process, including mid-stage preclinical trials (drug development).

For more information, please contact almeida@endobios.com